CompletedPhase 4

Study Evaluating Venlafaxine ER in Recurrent Depression

1,096 participantsStarted 2000-08

Plain-language summary

The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Clinical diagnosis for recurrent major depression Exclusion Criteria * The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant * Known hypersensitivity to venlafaxine or fluoxetine * History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder

Trial details

NCT IDNCT00046020

SponsorWyeth is now a wholly owned subsidiary of Pfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-10

View on ClinicalTrials.gov More Depressive Disorder, Major trials